Sun Zhiqiang, Duan Ranglong, Xing Dejun, Pang Xuan, Li Zhiying, Chen Xuesi
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022. China.
Tumor Hospital of Jilin Province, Changchun, 130012. China.
Curr Cancer Drug Targets. 2017;17(5):445-455. doi: 10.2174/1568009617666170109150430.
Due to their excellent biocompatibility and biodegradability, poly-epsiloncaprolactone and its derivative copolymers have been extensively studied as drug carriers in pharmaceutical and medical fields, especially for controlled release of anti-tumor drugs. Poly-epsiloncaprolactone based drug delivery systems lead to major advantages including uniform drug distribution, long term of degradation and drug release process, non-toxic in nature and cyto-compatible with body tissues. Approved by US Food and Drug Administration, poly-epsilon-caprolactone provides a promising platform for design and fabrication of anti-tumor drug delivery systems with controllable drug release behaviors.
This mini-review focused on the recent progress in application of poly-epsiloncaprolactone based materials for controlled release of cancer therapy drugs. A careful search was performed on web of science, mainly focused on the related papers published from 2013 to 2016.
Recent advances in applying poly-epsilon-caprolactone for controlled delivery and targeting release of chemical anti-tumor drugs were summarized in this mini-review. Benefited from the efforts of scientists all over the world, various chemotherapeutic drug delivery systems based on different formulations of poly-epsilon-caprolactone related materials have been evaluated. It has been widely recognized that the introduction of of poly-epsilon-caprolactone components into drug delivery systems would increase drug loading capacity, decrease leakage, prolong releasing period and result in controllable releasing rate. Especially with the development of environment-responsive delivery systems (pH-, thermo-, magnetic field- and light-responsive drug carriers), enhanced tumor cell targeting potential, as well as decreased systemic toxicity would be realized.
聚己内酯及其衍生物共聚物因其优异的生物相容性和生物降解性，在制药和医学领域作为药物载体得到了广泛研究，尤其是用于抗肿瘤药物的控释。基于聚己内酯的药物递送系统具有诸多主要优势，包括药物分布均匀、降解和药物释放过程持久、本质无毒且与身体组织具有细胞相容性。经美国食品药品监督管理局批准，聚己内酯为设计和制造具有可控药物释放行为的抗肿瘤药物递送系统提供了一个有前景的平台。
本综述聚焦于基于聚己内酯的材料在癌症治疗药物控释应用方面的最新进展。在科学网进行了仔细检索，主要关注2013年至2016年发表的相关论文。
本综述总结了聚己内酯在化学抗肿瘤药物控释和靶向释放应用方面的最新进展。得益于世界各地科学家的努力，基于不同配方的聚己内酯相关材料的各种化疗药物递送系统已得到评估。人们普遍认识到，将聚己内酯成分引入药物递送系统会提高药物载量、减少泄漏、延长释放期并实现可控释放速率。特别是随着环境响应性递送系统（pH响应、热响应、磁场响应和光响应药物载体）的发展，将实现增强的肿瘤细胞靶向潜力以及降低全身毒性。
